Literature DB >> 19945684

How to decide who to treat.

J A Kanis1, E V McCloskey, H Johansson, O Strom, F Borgstrom, A Oden.   

Abstract

Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Although treatments are available that have been shown to decrease the risk of fracture, problems arise in identifying individuals at high risk of fracture so that intervention can be effectively targeted. Practice guidelines, available in many countries, differ markedly in approach, but generally recommend treatments on the basis of a previous fragility fracture and a defined threshold for bone mineral density (BMD). Recent developments in fracture risk assessment include the availability of the FRAX tool by the World Health Organization (WHO) Collaborating Centre for Metabolic Bone Diseases at Sheffield, UK, that integrates the weight of clinical risk factors for fracture risk with or without information on BMD and computes the 10-year probability of fracture. The tool increases sensitivity without trading specificity and is now being used in the re-appraisal of clinical guidelines.

Entities:  

Mesh:

Year:  2009        PMID: 19945684     DOI: 10.1016/j.berh.2009.09.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  12 in total

Review 1.  The pharmacological management of osteoporosis.

Authors:  Amy E Riek; Dwight A Towler
Journal:  Mo Med       Date:  2011 Mar-Apr

Review 2.  Bone imaging and fracture risk assessment in kidney disease.

Authors:  Sophie A Jamal; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

3.  Appropriate use of anabolic treatment for severe osteoporosis.

Authors:  Silvano Adami; Maria Luisa Brandi; Pier Luigi Canonico; Giovanni Minisola; Salvatore Minisola; Umberto Tarantino
Journal:  Clin Cases Miner Bone Metab       Date:  2010-05

4.  Comparison of fracture risk prediction among individuals with reduced and normal kidney function.

Authors:  Kyla L Naylor; Amit X Garg; Guangyong Zou; Lisa Langsetmo; William D Leslie; Lisa-Ann Fraser; Jonathan D Adachi; Suzanne Morin; David Goltzman; Brian Lentle; Stuart A Jackson; Robert G Josse; Sophie A Jamal
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-05       Impact factor: 8.237

5.  Clinical characteristics and incidence of first fracture in a consecutive sample of post-menopausal women attending osteoporosis centers: The PROTEO-1 study.

Authors:  G C Isaia; V Braga; S Minisola; G Bianchi; A Del Puente; L Di Matteo; G Pagano Mariano; V M Latte; F D'Amico; C Bonali; P D'Amelio
Journal:  J Endocrinol Invest       Date:  2011 Jul-Aug       Impact factor: 4.256

Review 6.  Osteoporosis in paediatric patients with spina bifida.

Authors:  Humberto Marreiros; Humberto Filipe Marreiros; Clara Loff; Eulalia Calado
Journal:  J Spinal Cord Med       Date:  2012-01       Impact factor: 1.985

7.  What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?

Authors:  Bérengère Aubry-Rozier; Delphine Stoll; Marc-Antoine Krieg; Olivier Lamy; Didier Hans
Journal:  Clin Rheumatol       Date:  2012-11-01       Impact factor: 2.980

Review 8.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

9.  Social inequalities in osteoporosis and fracture among community-dwelling older men and women: findings from the Hertfordshire Cohort Study.

Authors:  Holly E Syddall; Maria Evandrou; Elaine M Dennison; Cyrus Cooper; Avan Aihie Sayer
Journal:  Arch Osteoporos       Date:  2012-02-14       Impact factor: 2.617

10.  Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Authors:  Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-08-03       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.